Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Other Gross PP&E Adjustments (2020 - 2025)

Xeris Biopharma Holdings' Other Gross PP&E Adjustments history spans 6 years, with the latest figure at -$13.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 29.51% year-over-year to -$13.8 million, compared with a TTM value of -$13.8 million through Dec 2025, up 29.51%, and an annual FY2025 reading of -$13.8 million, up 29.51% over the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$13.8 million at Xeris Biopharma Holdings, down from -$12.2 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $11.0 million in Q2 2022, with the low at -$19.5 million in Q4 2024.
  • Average Other Gross PP&E Adjustments over 5 years is -$8.0 million, with a median of -$13.8 million recorded in 2025.
  • Year-over-year, Other Gross PP&E Adjustments crashed 5426.05% in 2024 and then rose 29.51% in 2025.
  • Tracing XERS's Other Gross PP&E Adjustments over 5 years: stood at $7.6 million in 2021, then crashed by 82.28% to $1.3 million in 2022, then crashed by 1509.9% to -$18.9 million in 2023, then dropped by 2.98% to -$19.5 million in 2024, then rose by 29.51% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Other Gross PP&E Adjustments are -$13.8 million (Q4 2025), -$12.2 million (Q3 2025), and -$15.0 million (Q2 2025).